Safety, Growth, and Development After Dapagliflozin or Saxagliptin in Children With Type 2 Diabetes (T2NOW Follow-Up)
Prior treatment with dapagliflozin or saxagliptin for 52 weeks did not raise any safety concerns relating to height, weight, BMI, Tanner staging, growth and maturation markers, bone biomarkers, or AEs for up to 52 weeks following treatment discontinuation in pediatric patients with T2D.
Authors
- John T. Monyak
- Timothy Barrett (ORCID: https://orcid.org/0000-0002-6873-0750)
- Naim Shehadeh (ORCID: https://orcid.org/0000-0003-3158-6254)
- Cecilia Karlsson (ORCID: https://orcid.org/0000-0002-4299-8775)
- Pietro Galassetti
- Nayyar Iqbal
- Marie Bolin
- Jennifer Ostridge
Institutions
- Bar-Ilan University (IL)
- Rambam Health Care Campus (IL)
- AstraZeneca (Spain) (ES)
- AstraZeneca (United States) (US)
- University of Birmingham (GB)
Publication Details
- Journal
- The Journal of Clinical Endocrinology & Metabolism
- Published
- 2024-10-24
- DOI
- https://doi.org/10.1210/clinem/dgae723
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.36
Funders
- AstraZeneca
- AstraZeneca Pharma Poland